Amycretin, also known as zenagamtide, is an investigational, long-acting peptide drug being developed by Novo Nordisk for obesity, weight management, and type 2 diabetes. Amycretin is a dual GLP-1 receptor and amylin receptor agonist. Unlike semaglutide, which acts mainly through the GLP-1 receptor, amycretin activates both pathways through a single peptide molecule. Other names for this substance include zenagamtide, NN9487 and NNC0487-0111. Its PubChem SID is 518139431.
Amycretin
| CAS No | 3005889-81-3 |
|---|---|
| Molecular Formula | C₃₄₃H₅₅₀N₉₄O₁₁₆ |
| Molecular Weight | 7,846.60 g/mol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Amycretin, also known as zenagamtide, is an investigational, long-acting peptide drug being developed by Novo Nordisk for obesity, weight management, and type 2 diabetes.
The listed CAS number is 3005889-81-3.
The listed molecular formula is C₃₄₃H₅₅₀N₉₄O₁₁₆.
The listed molecular weight is 7,846.60 g/mol.
The source lists zenagamtide, NN9487 and NNC0487-0111.